Orientador: Luis Gustavo Modelli de Andrade / Resumo: Introdução: O transplante renal é considerado uma opção de terapia renal substitutiva segura para pacientes acima de 60 anos, entretanto, não há consenso sobre o melhor esquema imunossupressor para o paciente transplantado renal idoso. Objetivo: Avaliar a eficácia e segurança da combinação de tacrolimus e sirolimus em doses reduzidas comparada com a associação tacrolimus e micofenolato. Métodos: Estudo prospectivo randomizado de centro único comparando a combinação de tacrolimus e sirolimus em dose reduzida (grupo sirolimus) contra tacrolimus e micofenolato (grupo micofenolato). Foram incluídos todos os pacientes transplantados renais maiores de 60 anos. Foram avaliadas a sobrevida do paciente e enxerto, taxas de rejeição, função renal e incidência de infecção por citomegalovírus (CMV) em 12 meses de seguimento. Resultados: Foram randomizados 46 pacientes e analisados 44 casos (dois casos excluídos por não terem sido transplantados). As características basais dos grupos foram semelhantes sendo todos os casos transplantados com doador falecido e a maioria induzida com basiliximabe. O grupo micofenolato (n=23) e o grupo sirolimus (n=21) apresentaram sobrevida do paciente e enxerto censurado óbito respectivamente de 95,7% e 100% para o micofenolato e 79,6% e 90,5% para o sirolimus sem diferenças estatísticas. A incidência de rejeição e função renal ao longo de 12 meses foi semelhante entre os grupos. A infecção de ferida operatória, retardo de função do enxerto e proteinúria for... (Resumo completo, clicar acesso eletrônico abaixo) / Abstract: Introduction: Renal transplantation is considered safe for patients over 60 years, however, there is no consensus on the best immunosuppressive regimen in elderly. Objective: To evaluate the combination of tacrolimus and sirolimus in reduced dose in renal function comparing the combination tacrolimus and mycophenolate. Methods: A single-center prospective randomized study comparing the combination of tacrolimus and sirolimus in reduced dose (sirolimus group) against tacrolimus and mycophenolate (mycophenolate group). We included all kidney transplant patients over 60 years of age. We evaluated patient survival, biopsy prove acute rejection, renal function and incidence of cytomegalovirus (CMV) at 12 months of follow-up. Results: 46 patients were randomized and we analyzed 44 cases (two cases excluded because they were not transplanted). Baseline characteristics were similar between groups, all patients were transplanted with deceased donor, and the majority were induced with basiliximab. Mycophenolate group (n = 23) and sirolimus group (n = 21) had patient survival, and death censored graft survival respectively 95.7% and 100% for mycophenolate and 79.6% and 90.5% for the sirolimus without statistical differences. The incidence of acute rejection and kidney function over 12 months was similar between the groups. Infection of the surgical wound, delayed graft function and proteinuria were similar between groups. The total cholesterol and HDL cholesterol were higher in the siro... (Complete abstract click electronic access below) / Mestre

Orientador: Luís Gustavo Modelli de Andrade / Resumo: RESUMO Bruder R. Redução da Incidência de Citomegalovírus no esquema Sirolimo associado à Tacrolimo em paciente idoso transplantado renal. Tese (Doutorado). Faculdade de Medicina de Botucatu. Universidade Estadual Paulista, 2018. Introdução: O transplante renal é considerado uma opção de terapia renal substitutiva segura para pacientes acima de 60 anos, entretanto, não há consenso sobre o melhor esquema imunossupressor para o paciente transplantado renal idoso. Objetivo: Avaliar a incidência de infecção por citomegalovírus na combinação de tacrolimo e sirolimo em doses reduzidas comparada com a associação tacrolimo e micofenolato. Métodos: Estudo prospectivo randomizado de centro único comparando a combinação de tacrolimo e sirolimo em dose reduzida (grupo sirolimo) contra tacrolimo e micofenolato (grupo micofenolato). Foram incluídos todos os pacientes transplantados renais maiores de 60 anos. Foram avaliadas a incidência de infecção por citomegalovírus (CMV), a sobrevida do paciente e enxerto, taxas de rejeição e função renal em 12 meses de seguimento. Resultados: Foram randomizados 46 pacientes e analisados 44 casos (dois casos excluídos por não terem sido transplantados). As características basais dos grupos foram semelhantes sendo todos os casos transplantados com doador falecido e a maioria induzida com basiliximab. O grupo micofenolato (n=23) e o grupo sirolimo (n=21) apresentaram sobrevida do paciente e enxerto censurado óbito respectivamente de 95,7% e 100% para o mi... (Resumo completo, clicar acesso eletrônico abaixo) / Abstract: ABSTRACT Bruder R. Reduced incidence of cytomegalovirus in the Sirolimus associated with tacrolimus in elderly kidney transplant patient. Tese (Doutorado). Faculdade de Medicina de Botucatu. Universidade Estadual Paulista, 2018. Introduction: Renal transplantation is considered safe for patients over 60 years, however, there is no consensus on the best immunosuppressive regimen in elderly. Objective: To evaluate the incidence of cytomegalovirus infection in the combination of tacrolimus and sirolimus in reduced doses compared to the combination tacrolimus and mycophenolate. Methods: A single-center prospective randomized study comparing the combination of tacrolimo and sirolimo in reduced dose (sirolimo group) against tacrolimo and mycophenolate (mycophenolate group). We included all kidney transplant patients over 60 years of age. The incidence of cytomegalovirus (CMV) infection, patient survival and graft, rejection rates and renal function were evaluated at 12 months of follow-up. Results: 46 patients were randomized and we analyzed 44 cases (two cases excluded because they were not transplanted). Baseline characteristics were similar between groups, all patients were transplanted with deceased donor, and the majority were induced with basiliximab. Mycophenolate group (n = 23) and sirolimo group (n = 21) had patient survival, and death censored graft survival respectively 95.7% and 100% for mycophenolate and 87,3% e 90,5% for the sirolimo without statistical differences. T... (Complete abstract click electronic access below) / Doutor

Os objetivos do estudo consistiram em verificar o impacto da infecção congênita por CMV ao nascer e avaliar potenciais preditores prognósticos de anormalidades tardias em uma coorte de criança s com esta infecção. Métodos: Por meio de uma triagem neonatal, 66 de 11.957 crianças foram identificadas como portadoras de infecção congênita por CMV. Todas as crianças infectadas sintomáticas e assintomáticas foram avaliadas ao nascimento por meio de exame físico detalhado, avaliação auditiva, fundoscopia ocular, neurossonografia transfontanelar (NTF) realizada por neurorradiologista infantil e quando alterada, foram submetidas à ressonância magnética de encéfalo (RMc). Análise de regressão logística foi realizada para verificar a associação de potenciais fatores de risco para ocorrência de surdez neurossensorial relacionada ao CMV e/ou presença de achados anormais em NTF e/ou RMc. A análise da Curva ROC foi utilizada para avaliar a associação da carga do DNA do CMV expresso em log10, com a presença de sintomas ao nascer, achados anormais em NTF e/ou RMc e ocorrência de surdez neurosensorial. Resultados: Em 66 crianças infectadas, os sinais clínicos sugestivos de infecção congênita ao nascer foram observados em 8/66 (12,12%; IC95%: 5,74-23,03), sendo considerados sintomáticos. As 58 crianças restantes foram considerados assintomáticos. A surdez neurossensorial foi observada em 8/66 (12,12%; IC95%: 5,74-23,03%) das crianças. Destas, 4/58 (6,9%; IC95%: 2,23- 17,54%) e 4/8 (50%; IC95%: 17,44-82,55%) crianças eram assintomáticas e sintomáticas, respectivamente. Achados de NTF e/ou RMc sugestivas de infecção congênita foram observadas em 7 de 8 crianças sintomáticas (87,5%; IC95%: 46,67-99,34%). Dentre as 58 assintomáticas, 53 (92,4%) completaram todas as avaliações e destas 29/52 apresentaram alterações sugestivas de infecção congênita em NTF e/ou RMc (55,7%; IC95%: 41,41 - 69,27%). O achado mais comum foi a vasculopatia lenticuloestriada acompanhado ou não de cistos subpendimários (13/29: 43.3%). Outros achados anormais foram os cistos subpendimários como achado isolado (11/29: 37.9%), calcificação única ou periventricular com ou sem áreas de gliose (4/29: 13,8%) e ventriculomegalia (4/29: 13,8%). Análise de regressão logística mostrou que apenas a presença de sintomas clínicos ao nascer foi preditivo para a ocorrência de surdez neurossensorial. Achados de neuroimagens (NTF e/ou RMc) foram observados em 3 de 4 crianças assintomáticas (75%) enquanto 26 (54,2%) de 48 crianças sem surdez tinham avaliações normais de NTF e/ou RMc (p=0,42; RR:2,38: IC95%: 0,26-21,39). Nenhum dos outros fatores de risco foram independentemente associados com surdez. A presença de plaquetopenia e/ou níveis altos de gama glutamil transferase (?GT) foi associado com a presença de achados anormais em NTF e/ou RMc uma análise univariada. O poder discriminatório pela determinação do ponto de corte do valor da carga do DNA do CMV foi avaliada pela área abaixo da curva ROC (AUC) e não houve associação entre a carga viral e a ocorrência de surdez e/ou achados anormais de NTF e/ou RMc. Conclusões: Embora a triagem neonatal da infecção congênita por CMV permita identificar a maioria das crianças infectadas que são clinicamente assintomáticas ao nascer, uma proporção significante destas crianças poderá ser beneficiada por uma avaliação do sistema nervoso central através de NTF, uma vez que, achados anormais são muito frequentes. Embora não tenha sido possível determinar fatores independentemente preditivos de ocorrência de surdez neurossensorial, os achados de NTF podem ser potenciais fatores preditivos de anormalidades tardias em crianças assintomáticas. / The objectives of this study were to verify the impact of congenital cytomegalovirus (CMV) infection at birth and to evaluate potential prognostic predictors of late abnormalities in a cohort of children with this infection. Methods: By means of a CMV neonatal screening, 66 of 11.957 infants were identified as congenitally infected. Infants with and without clinical abnormalities detectable at birth underwent physical examination, cranial ultrasound performed by a paediatric radiologist and/or cranial magnetic resonance imaging, ocular fundoscopy, and hearing evaluation using evoked otoacoustic emissions and auditory brainstem response. Logistic regression analysis was carried out to verify the association between the risk factors for occurrence of hearing loss related to CMV and/ or abnormal cranial ultrasound findings. ROC curve was plotted using the log10 value of CMV DNA load to evaluate the association between viral load and clinical symptoms at birth, abnormal cranial ultrasound findings and hearing loss. Results: Of all 66 infected children, the clinical signs suggestive of congenital infection at birth were observed in 8/66 (12.12%; IC95%: 5.74- 23.03) symptomatic infants. Sensorineural hearing loss was observed in 8/66 (12,12%; IC95%: 5.74-23.03%) children. Of these, 4/58 (6,9%; IC95%: 2.23-17.54%) and 4/8 (50%; IC95%: 17,44-82.55%) children were asymptomatic and symptomatic, respectively. Cranial ultrasound findings suggestive of congenital infection were observed in 7 of the 8 symptomatic children (87.5%; IC95%: 46.67-99.34%). Among the 58 asymptomatic infants, 53 underwent complete evaluation and 29/52 had abnormal cranial ultrasound results (55,7%; IC95%: 41.41 - 69,27%). The most prevalent findings was lenticulostriate vasculopathy with subependymal pseudocysts present in 13 of the /29 (43.3%) infants with cranial ultrasound. Other abnormal findings were isolated subependymal pseudocysts (11/29: 37.9%); single or periventricular calcifications and/or gliosis (4/29: 13.8%); and ventriculomegaly (4/29: 13,8%). Logistic regression analysis showed that only the presence of clinical findings predicted the occurrence of hearing loss. Cranial ultrasound findings were observed in 3 of asymptomatic infants (75.0%) while 26 (54.2%) of 48 infants with no hearing loss had abnormal imaging features (p=0,42; RR:2,38: IC95%: 0,26-21,39). None of the other factors risk were independely associated with development of hearing loss. The presence of thrombocytopenia and/or high level of gamma-glutamyltranspeptidase (?GT) was associated with cranial ultrasound findings on univariated analysis. No discrimination power was achieved using the area under the ROC curve to verify the association between CMV DNA load in the urine of the infected children and the developing of hearing loss, presence of cranial ultrasound findings and clinical signs at birth. Conclusions: Although a neonatal screening of cCMV will identify the majority of infected infants who are clinically asymptomatic, a significant proportion of them could benefit from a central nervous system image evaluation, since abnormal findings are frequent. Althoug it was not possible to determine risk factors that are independently associated to development of sensorineural hearing loss, cranial ultrasound findings could be a potential prognostic markers of adverse outcomes of congenital CMV in asymptomatic infants.

The human body is exposed to a multitude of prevalent viruses, requiring ongoing surveillance and protection by the immune system. Maintenance of human anti-viral adaptive immunity in diverse tissue sites is determined by a multitude of factors and critical for long-term protection against repeat exposure to viral infection. Yet, studies of anti-viral immunity have primarily been limited to animal studies and studies of peripheral blood in humans. Studies in mice have demonstrated that memory T cells in tissues provide superior protection against viral infection compared to circulating T cells, particularly tissue-resident memory T cells (TRM), which remain in tissues long-term without re-entering circulation. However, much remains to be understood about how anti-viral immune responses are maintained in human tissues and how adaptive immune cells in various tissues sites function upon re-exposure to viral antigens. We have established a human tissue resource through a collaboration with LiveOnNY, a local organ procurement organization, to obtain blood and multiple lymphoid and mucosal sites from donors of all ages. Using this tissue resource, we employed comprehensive cellular and molecular analysis to investigate tissue immunity to three prevalent but distinct viruses—influenza A, CMV, and SARS-CoV-2. We compared CD8+ T cells recognizing ubiquitous and longstanding viruses influenza A and CMV across multiple tissue sites of 58 organ donors ages 1-78 years in order to elucidate how covariates of virus, tissue, age, and sex impact the anti-viral immune response. Using flow cytometry, T cell receptor repertoire sequencing, functional assays, and single-cell transcriptional profiling, we showed that virus specificity and tissue localization are the primary drivers of anti-viral T cell immune responses in the human body, with age and sex further influencing T cell subset differentiation. Specifically, virus specificity correlated with virus-specific T cell distribution, memory subset differentiation, and clonal repertoire, while tissue localization determined overall subset distribution and functional responses. We further investigated the tissue-localized immune response to emergent SARS-CoV-2. By examining multiple tissues of organ donors who had recovered from natural infection by SARS-CoV-2, we showed that adaptive memory immune responses persisted months after infection, with memory T and B cells preferentially localized in the lung and lung-associated lymph node. Persisting memory cell populations included tissue-resident T and B cells, particularly in the lung, as well as germinal center B cells in the lung-associated lymph node along with follicular helper T cells, indicating ongoing generation of humoral immunity. Together, these findings highlight the importance of tissue-localized anti-viral immunity and help to define characteristics of site-specific protective immunity that may be leveraged for the development of more effective treatment and prevention strategies.

京都大学 / 0048 / 新制・課程博士 / 博士(医学) / 甲第21667号 / 医博第4473号 / 新制||医||1035(附属図書館) / 京都大学大学院医学研究科医学専攻 / (主査)教授 小柳 義夫, 教授 中川 一路, 教授 長船 健二 / 学位規則第4条第1項該当 / Doctor of Medical Science / Kyoto University / DFAM

No description available.

No description available.

Genom en digital enkätundersökning har kunskapsläget om medfödd Cytomegalovirus (CMV) i Sverige undersökts. Virusinfektionen är en av de vanligaste i världen och kan innebära skador på foster om smitta överförs från moder till foster under en graviditet. Av de 304 individer som besvarade enkäten hade 21 % hört talas om CMV men endast 10 % hade kunskap om hur man skyddar sig mot CMV. Att denna information inte nått ut till fler stämmer överens med andra undersökningar som genomförts i världen, men det preliminära genomsnittliga kunskapsläget för svenskar är lågt jämfört med övriga Europa. Blivande föräldrar behöver få veta riskerna med medfödd CMV och sambandet det har med rutiner i vardagen, som att dela bestick eller pussa syskon i yngre förskoleålder på munnen under en graviditet. Även i nära anslutning till COVID-19-pandemin tycks hygienrutiner inte blivit tillräckligt etablerade och säkra för att skydda även de svagaste i samhället mot onödig risk att smittas av medfödd CMV infektion som kan medföra allvarliga och bestående skador. / Through a digital survey, the level of knowledge about congenital Cytomegalovirus (CMV) has been investigated in Sweden. The virus infection is one of the most common worldwide and can cause damage to the fetus if the infection is transmitted from mother to fetus during pregnancy. Out of the 304 individuals who responded to the survey, 21% had heard of CMV, but only 10% had knowledge of how to protect themselves from CMV. The fact that this information has not reached more people is consistent with other studies conducted globally, but the preliminary knowledge level among Swedes is low compared to the rest of Europe. Parents need to be aware of the risks associated with congenital CMV infection and its connection to daily routines, such as sharing utensils or kissing younger siblings on the mouth during pregnancy. Even in the immediate aftermath of the COVID-19 pandemic, hygiene practices do not seem to have been sufficiently established and secure to protect the most vulnerable in society also from unnecessary risks of CMV transmission, which can lead to permanent and serious injuries.

No description available.

No description available.